| Objective:To investigate the relationship between the fluctuation of its value and the efficacy of chemotherapy,detecting the levels of plasma heat shock protein 90alpha(Hsp90α)and conventional lung cancer tumor markers in the patients with non-small cell lung cancer before and after chemotherapy.Method:In the experimental group,40 patients with lung cancer were divided into adenocarcinoma group(20 cases)and squamous cell carcinoma group(20 cases),according to the pathological type the lung cancer group is divided into adenocarcinoma group(20 cases)and squamous cell carcinomas(20 cases),all enrolled patients with lung cancer were treated with platinum-based chemotherapy,according to the RECIST1.1 criteria lung cancer patients can be divided into effective group(CR + PR,SD = 24 cases)and invalid group(PD = 16cases),as the same time physical examination as a control.The levels of Hsp90 alpha and tumor markers in lung cancer group and control group were determined by enzyme-linked immunosorbent assay(ELISA).ROC curve was used to analyze the optimal critical point of Hsp90 alpha for the clinical diagnosis of lung cancer and the optimal critical point for the effective diagnosis of chemotherapy with different chemotherapy cycles.Analysis of variance was used to compare the Hsp90 alpha expression levels in the effective and ineffective groups of 3 cycles of chemotherapy,and the differences between the two groups were further analyzed by the Bonferroni method.Result:1.There was no statistical difference in the expression level of Hsp90 alpha in age,sex or pathological type(P > 0.05).2.The expression level of Hsp90 alpha in the lung cancer group was significantly higher than that in the healthy control group(178.07±101.17 VS 43.46±38.12)ng/m L,and the difference was statistically significant(P<0.0001).3.ROC curve analysis showed that the optimal critical value of Hsp90 alpha in the diagnosis of lung cancer was 99.15ng/m L,the sensitivity was 82.5%,and the specificity was 93.3%,showing a statistical difference(AUC=0.917,P<0.001),and Hsp90 alpha in combination with tumor markers CEA,SCC,CA125,CA15-3,CYFRA21-1 and NSE had the highest diagnostic value,showing a statistical difference(AUC=0.993,P< 0.05).4.There was no statistical difference in the expression level of Hsp90 alpha,SCC,CEA,CA125,CA153 and CYFRA211 between adenocarcinoma group and squamous cell carcinoma group(P > 0.05).The expression level of NSE in adenocarcinoma was significantly higher than that in squamous cell carcinoma(57.047±58.50369 VS 11.016±7.26214)ng/m L,showing a statistical difference(P <0.05).5.The expression level of Hsp90 alpha on the 1st day before the first cycle of chemotherapy(178.0723±101.1681)ng/m L was significantly higher than that on the3 rd day after the first cycle of chemotherapy(129.569±90.52642)ng/m L(P <0.05).There was no statistically significant difference in the expression level of Hsp90 alpha 1 day before and 3 days after the second cycle of chemotherapy(P > 0.05).and t In the effective group,the expression level of Hsp90 alpha on the 1st day before the second cycle of chemotherapy was significantly lower than tthat on the 3rd day after the second cycle of chemotherapy(65.175±47.86918 VS 38.3008±31.26915)ng/m L(P < 0.05).In the ineffective group,he expression level of Hsp90 alpha on the 1st day before the second cycle of chemotherapy was significantly lower than tthat on the 3rd day after the second cycle of chemotherapy(321.0164±87.55881 VS242.7062±89.43013)ng/m L(P < 0.05).6.In this study,the expression level of Hsp90 alpha in the 1 day before the first cycle of chemotherapy,the second cycle of chemotherapy and the third cycle of chemotherapy were statistically different(P < 0.05),between the effective group and the ineffective group.7.In effective group,Hsp90 alpha expression level in the first cycle of chemotherapy and the second cycle of chemotherapy was statistically difference(P <0.05),Hsp90 alpha expression level in the first cycle of chemotherapy and the third cycle of chemotherapy was statistically difference(P < 0.05),Hsp90 alpha expression level in the second cycle of chemotherapy and the third cycle of chemotherapy was no statistically difference(P > 0.05).However,In the ineffective group,there were statistical differences in the expression levels of Hsp90 alpha in 3 cycles of chemotherapy(P < 0.05).8.ROC curve analysis showed that Before the first cycle of chemotherapy,the optimal critical value of Hsp90 alpha in the diagnosis of chemotherapy efficacy was113.4ng/m L,with a statistical difference(AUC=0.721,P<0.05);Before the second cycle of chemotherapy,the optimal critical value of Hsp90 alpha in the diagnosis of chemotherapy efficacy was 204.15ng/m L,with statistical difference(AUC = 0.995,P< 0.001);There was no statistical difference in the diagnosis of chemotherapy efficacy before the third cycle of chemotherapy(P >0.05).Conclusion:Hsp90 alpha can be used as a new tumor marker in the diagnosis of lung cancer,and improve the detection level of lung cancer in combination with other tumors.The expression level of Hsp90 alpha was not related to age,sex or pathological type,but was related to chemotherapy cycle of lung cancer.Comparing the changes of Hsp90 alpha level before and after chemotherapy can provide an important reference value for judging whether chemotherapy is effective,and it is more feasible to evaluate the efficacy of chemotherapy before the second cycle of chemotherapy. |
PDF Full Text Request